Hot Features
프리미엄
Adolor Corp. (MM) (ADLR)
NASDAQ
브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) and Adolor Corporation (NASDAQ: ADLR) today announced the results of Cubist’s initial tender offer to purchase all of the...
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) and Adolor Corporation (NASDAQ: ADLR) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust...
Adolor Corporation (NasdaqGM: ADLR) today reported net sales of ENTEREG® (alvimopan) of $7.8 million for the three months ended September 30, 2011, a 20% increase compared to...
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the commencement of its tender offer for all outstanding shares of the common stock of Adolor Corporation (NASDAQ:...
Bull & Lifshitz, LLP announces an investigation into possible breaches of fiduciary duty in connection with the proposed sale of Adolor Corporation (NASDAQ: ADLR) (referred to...
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Adolor Corporation (“Adolor” or the “Company”) (Nasdaq:...
Glancy Binkow & Goldberg LLP announces that it is investigating potential claims against the board of directors of Adolor Corporation (“Adolor” or the “Company”) (NASDAQ:ADLR...
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Adolor Corp. (“Adolor” or the “Company”...
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Adolor Corporation (“Adolor” or the “Company”) (Nasdaq:...
Law Offices of Howard G. Smith announces that it is investigating potential claims against the board of directors of Adolor Corporation (“Adolor” or the “Company”...
| 기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
